Business Context and Reporting Period
This Form 8-K was filed by OncoGenex Pharmaceuticals, Inc. (noted as "ACHIEVE LIFE SCIENCES, INC." in request metadata) on November 10, 2016. The filing serves to announce the Company's financial results for the third quarter of 2016 via a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover sheet for the 8-K filing and does not contain specific financial data. It references a press release (Exhibit 99.1) for details on revenue, profit, cash flow, margins, debt, and liquidity. Consequently, no specific financial metrics are available in the source text.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It only indicates that results for the third quarter of 2016 were announced.
Guidance, Outlook, and Risks
The text does not contain management commentary, guidance, outlook, or specific risk factors. It notes that the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor is it incorporated by reference except as expressly set forth.
Investor Verification Checklist
- Verify the discrepancy between the request metadata ("ACHIEVE LIFE SCIENCES, INC.") and the filing registrant ("ONCOGENEX PHARMACEUTICALS, INC.").
- Review Exhibit 99.1 (the press release) to obtain actual Q3 2016 financial figures, as they are absent from the 8-K cover text.
- Confirm the legal status of the financial data, noting the disclaimer that the press release is "furnished" rather than "filed."
- Check for subsequent filings to see if the furnished data was later incorporated by reference.